New Real-World Evidence for Pepaxti in Multiple Myeloma at ASH 2026
Oncopeptides to present clinical outcomes for melflufen in refractory cancer patients in New Orleans.
1ASH 2026 Presentation
Oncopeptides AB will present two abstracts at the 68th American Society of Hematology Annual Meeting. The event is scheduled for December 12–15, 2026, in New Orleans, USA. This gathering serves as a primary platform for sharing advancements in hematology, specifically focusing on complex cancer treatments and emerging clinical research findings.
2Focus on Pepaxti
The presentations center on Pepaxti, also known as melflufen, which is developed by the biotech firm Oncopeptides. This drug is specifically designed for patients suffering from relapsed, refractory multiple myeloma. The research highlights real-world clinical outcomes, providing data beyond controlled trials to show how the therapy performs in diverse patient populations.
3Targeting Refractory Myeloma
Multiple myeloma is a cancer of plasma cells that remains difficult to treat, especially when it becomes refractory. Patients in this category have often undergone multiple previous lines of therapy without success. The upcoming data aims to clarify the role of melflufen in managing these heavily pretreated cases within clinical practice settings.
4Real-World Evidence Significance
Real-world evidence is increasingly vital for validating drug efficacy outside the rigid parameters of randomized clinical trials. By analyzing actual patient outcomes, Oncopeptides seeks to demonstrate the practical utility of Pepaxti. This approach helps clinicians understand how the drug interacts with standard care pathways and diverse patient health profiles in reality.
5Oncopeptides Corporate Context
Oncopeptides AB, listed on Nasdaq Stockholm under the ticker ONCO, specializes in developing targeted therapies for difficult-to-treat cancers. Their focus on melflufen represents a strategic effort to address unmet medical needs in hematological oncology. The company's participation at ASH 2026 underscores their commitment to transparency and ongoing clinical validation of products.
6Clinical Data Utility
The two accepted abstracts provide a detailed look at how melflufen functions in real-world scenarios. By presenting this data at a major international conference, the company allows for peer review and discussion among global experts. This process is essential for integrating new evidence into existing treatment guidelines for multiple myeloma patients.
7Advancing Hematological Care
The American Society of Hematology meeting attracts thousands of researchers and clinicians from around the world. Presenting at this venue ensures that the findings regarding Pepaxti reach a wide audience of specialists. This exchange of information is critical for refining therapeutic strategies and improving long-term outcomes for patients with refractory cancers.
8Future Clinical Implications
The findings to be shared in December 2026 could influence how oncologists approach heavily pretreated multiple myeloma cases. If the real-world data confirms positive outcomes, it may support broader adoption of melflufen in clinical settings. Stakeholders will monitor these presentations to assess the drug's long-term viability and its impact on patient survival.
Original article: News-Medical — New Real-World Evidence for Pepaxti in Multiple Myeloma at ASH 2026